BioPharmSignal logoBioPharmSignal

Biotech News

ANI Pharmaceuticals Announces the Launch of Duloxetine Delayed-Release Capsules

ANI Pharmaceuticals (ANIP)ANI PharmaceuticalsCommercial

ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced the launch of Duloxetine Delayed-Release Capsules 20, 30 and 60 mg. ANI’s Duloxetine Delayed-Release Capsules are the generic version of the reference listed drug (RLD) Cymbalta ® .

Related news

ANIPANI Pharmaceuticals2026-04-13 10:50 EST

ANI Pharmaceuticals Announces the Launch of Carbamazepine Extended-Release Capsules

ANIPANI Pharmaceuticals2026-04-20 10:50 EST

ANI Pharmaceuticals Announces the FDA Approval and Launch of Pimozide Tablets with 180 Day CGT Exclusivity

AMRXAmneal Pharmaceuticals2026-08-10 12:00 EST

Amneal Completes Acquisition of Kashiv BioSciences, Creating a Global Biosimilar Leader

SNYSanofi2026-10-12 16:05 EST

Sanofi: Information concerning the total number of voting rights and shares – September 2026

AMRXAmneal Pharmaceuticals2026-09-18 20:01 EST

Amneal Announces FDA Approval and Launch of Lanreotide Injection

View all latest news

ANI Pharmaceuticals

Rare-Disease and Specialty Pharmaceuticals ANI Pharmaceuticals develops and commercializes medicines across rare disease, ophthalmology and established pharmaceutical markets. Its model combines branded specialty products with a portfolio of generic medicines. Cortrophin Gel Purified Cortrophin Gel is an adrenocorticotropic hormone...

Recent company news

ANIPANI Pharmaceuticals2026-10-19 10:55 EST

ANI Pharmaceuticals Announces the Launch of Duloxetine Delayed-Release Capsules

ANIPANI Pharmaceuticals2026-10-12 10:55 EST

ANI Pharmaceuticals Announces Positive Phase 4 Open-Label, Single-Arm SYNCHRONICITY Clinical Trial Results Presented as Late Breaking Oral Presentation at the American Academy of Ophthalmology 2026 Annual Meeting

ANIPANI Pharmaceuticals2026-09-30 10:55 EST

ANI Pharmaceuticals Announces New Fluocinolone Acetonide Intravitreal Implant Data to be Presented at the American Academy of Ophthalmology 2026 Annual Meeting

ANIPANI Pharmaceuticals2026-09-23 10:55 EST

ANI Pharmaceuticals Announces the FDA Approval of Everolimus Tablets for Oral Suspension

ANIPANI Pharmaceuticals2026-09-03 10:55 EST

ANI Pharmaceuticals to Present at September Investor Conferences

Stock data

Close
72.24 USD
Market cap
1.7B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States